Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents
Potent and Sustained Antiviral Response of Raltegravir-based Highly Active Antiretroviral Therapy in HIV Type 1-infected Children and Adolescents
复制标题
DOI：
10.1097/inf.0b013e31824580e8
复制
发表时间：
2012-03-01
影响因子：
3.6
通讯作者：
Angeles Munoz-Fernandez, Ma
中科院分区：
文献类型：
--
作者：
Briz, Veronica;Leon-Leal, Juan A.;Angeles Munoz-Fernandez, Ma
背景资料：有儿科患者接受许多高活性抗逆转录病毒治疗（HAART）方案，需要耐药突变复杂HAART effective therapeutic.Methods：这是一个多中心的回顾性研究，19多药耐药的儿童和青少年从2007年7月至2009年10月入组。患者为无应答者，因为在既往抗逆转录病毒治疗史中未观察到HIV 1型（HIV-1）RNA降低至无法检测的水平。雷特格韦（RAL）为基础的挽救治疗的长期有效性进行了评估，通过纵向分析的免疫学，病毒学和临床状态的patients.Results：中位年龄为16.0（15.0-18.0）岁。基线时，中位HIV-1 RNA为10，000（4.0 log（10）拷贝/mL）（四分位距[IQR]：4300- 83，000），中位CD 4（+）T细胞计数为329（18.2%细胞/μ L）（IQR：175-452）。17/19例（89%）患者的骨干方案包括至少1种完全活性药物。HAART（包括RAL）的中位随访时间为80.1周（IQR：49.4-96.4）：16/19（84%）暴露>120周，6/19（32%）>100周。在基于RAL的治疗后，4/19（21%）例患者获得了HIV-1 RNA
Background: There are pediatric patients receiving many highly active antiretroviral therapy (HAART) regimens entailing drug resistance mutations that complicate HAART effective therapies.Methods: This was a multicenter retrospective study of 19 multidrug-resistant children and adolescents enrolled from July 2007 to October 2009. Patients were nonresponders because no reduction in HIV type 1 (HIV-1) RNA to undetectable levels was observed during their previous antiretroviral treatment history. The long-term effectiveness of raltegravir (RAL)-based salvage therapy was assessed through a longitudinal analysis of immunologic, virologic, and clinical status of the patients.Results: Median age was 16.0 (15.0-18.0) years. At baseline, median HIV-1 RNA was 10,000 (4.0 log(10) copies/mL) (interquartile range [IQR] : 4300-83,000), and median CD4(+)T-cell count was 329 (18.2% cells/mu L) (IQR: 175-452). The backbone regimen included at least 1 fully active drug in 17/19 (89%) patients. Median follow-up with HAART including RAL was 80.1 weeks (IQR: 49.4-96.4): 16/19 (84%) exposed for >120 weeks and 6/19 (32%) >100 weeks. After RAL-based therapy, 4/19 (21%) patients achieved HIV-1 RNA